CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hansoh Pharma reports 61.3% response rate for HS-20122 in Phase 1 trial in EGFR-mutant lung cancer after TKI failure

By Public Technologies
  • Hansoh Pharma presented Phase 1 results for cancer drug HS-20122 at ESMO in Madrid on October 24, 2026.
  • The treatment showed antitumor activity across advanced solid tumors, particularly EGFR-mutated lung cancer following failure of EGFR-targeted therapy.
  • Safety was manageable, with most treatment-related adverse events mild to moderate; serious events primarily involved blood abnormalities.
  • The findings support further development in multiple solid tumors, including EGFR-mutated lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk